Ephrin Receptor Inhibitor

Ephrin Receptor Inhibitors (24):

Cat. No.	Product Name	Effect	Purity

HY-18007

ALW-II-41-27	Inhibitor	99.33%
ALW-II-41-27 is a Eph family tyrosine kinase inhibitor with an IC₅₀ of 11 nM for Eph2.

HY-13258A

NVP-BHG712	Inhibitor	99.71%
NVP-BHG712 is an oral active EphB4 kinase autophosphorylation inhibitor, with IC₅₀ values of 3.3 nM and 3.0 nM for EphA2 and EphB4, respectively.

HY-18833

ALW-II-49-7	Inhibitor	99.97%
ALW-II-49-7 is a selective EphB2 kinase inhibitor with an EC₅₀ value of 40 nM in cell.

HY-18832

AWL-II-38.3	Inhibitor	99.71%
AWL-II-38.3 is a potent ephrin-A receptor (EphA3) kinase inhibitor. AWL-II-38.3 does not exhibit significant cellular activity against Src-family kinases nor against b-raf.

HY-107460

LDN-211904 oxalate	Inhibitor	99.0%
LDN-211904 oxalate is a potent and reversible EphB3 inhibitor with an IC₅₀ of 79 nM. LDN-211904 oxalate shows good metabolic stability in mouse liver microsomes. LDN-211904 oxalate with Cetuximab (HY-P9905) could be effective in inhibiting STAT3-activated colorectal cancer (CRC) stemness and Cetuximab resistance in CRC.

HY-P991975

Anti-EphB3 Antibody	Inhibitor
Anti-EphB3 Antibody is an anti-EphB3 antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991965

Anti-Ephrin-B2 Antibody	Inhibitor
Anti-Ephrin-B2 Antibody is an anti-Ephrin-B2 antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-10654

EphB4-IN-2	Inhibitor
EphB4-IN-2 (compound 66) is a tyrosine kinase inhibitor with an IC₅₀ value of 1.6 nM against human EphB4, and exhibits selectivity toward kinases bearing threonine gatekeeper residues. EphB4-IN-2 also has high ligand efficiency.

HY-P990627

Anti-EphA2 Antibody (1C1)	Inhibitor	99.9%
Anti-EphA2 Antibody (1C1) (MEDI-547 antibody) is an anti-EphA2 monoclonal antibody. Anti-EphA2 Antibody (1C1) can induce degradation of EphA2 protein. Anti-EphA2 Antibody (1C1) conjugated with McMMAF (HY-15578) can form an antibody-conjugated drugs, which has potent antitumor activity. Anti-EphA2 Antibody (1C1) can be used for the research of cancer, such as prostate cancer and glioma.

HY-114199

Eph inhibitor 1	Inhibitor	99.92%
Eph inhibitor 1 is a potent Eph inhibitor. Eph inhibitor 1 has the potential for the research of neurological disorders.

HY-169849

EphA2 antagonist 1	Inhibitor
EphA2 antagonist 1 (4b) is a bile acid conjugate and an ephrin type-A receptor 2 (EPHA2) inhibitor.

HY-P2264

KYL peptide	Inhibitor	99.65%
KYL peptide, an antagonistic peptide, selectively targets EphA4 receptor (IC₅₀:4.22 μM, Kd:1.3 μM). KYL peptide binds to the ligand-binding domain of EphA4, effectively alleviates Aβ-induced synaptic dysfunction and synaptic plasticity defects in AD mice. KYL peptide can promote nerve regeneration after injury and modulating immune responses.

HY-P990405

Anti-EphB2 Antibody	Inhibitor	99.36%
The Anti-EphB2 Antibody is a CHO expressed human antibody that targets EphB2. The Anti-EphB2 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-EphB2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-131005

Eph inhibitor 2	Inhibitor	99.00%
Eph inhibitor 2 (Example 35) is a Eph family tyrosine kinase inhibitor.

HY-P10412A

A11 acetate	Inhibitor	98.48%
A11 (ANXA1-derived 11 amino acid-long peptide) acetate is a ANXA1-EphA2 interaction-blocking peptide. A11 acetate reduces ANXA1 bound to EphA2 and increases Cbl (the E3 ubiquitin ligase of EphA2) bound to EphA2. A11 acetate inhibits the proliferation, migration and invasion of nasopharyngeal carcinoma cells. A11 acetate inhibits angiogenesis. A11 acetate can be used in studies related to nasopharyngeal carcinoma.

HY-161171

Antimalarial agent 37	Inhibitor
Antimalarial agent 37 (compound 33) is a selective inhibitor against Type Ⅱ kinase with antiplasmodial activity. Antimalarial agent 37 exhibited cytotoxicity and selectivity towards cancer cells HepG2 and MCF 7.

HY-14575

Nastorazepide hemicalcium	Inhibitor
Nastorazepide (Z-360) hemicalcium is an orally active 1,5-benzodiazepine derivative and gastrin/CCK-2 receptor antagonist. Nastorazepide hemicalcium inhibits the specific binding of [³H]CCK-8 to the human CCK-2 receptor with a K_i value of 0.47 nM. Nastorazepide hemicalcium inhibits IL-1β, ephrin B1, VEGF, and HIF-1alpha, reduces Akt and NR2B phosphorylation. Nastorazepide hemicalcium has antitumor activity against pancreatic cancer. Nastorazepide hemicalcium inhibits colorectal cancer liver metastasis and relieves pain.

HY-136358

LDN-211904	Inhibitor
LDN-211904 is a potent and reversible EphB3 inhibitor with an IC₅₀ of 79 nM. LDN-211904 shows good metabolic stability in mouse liver microsomes. LDN-211904 with cetuximab could be effective in inhibiting STAT3-activated colorectal cancer (CRC) stemness and Cetuximab (HY-P9905) resistance in CRC.

HY-14979

ML786	Inhibitor
ML786 is a potent and orally bioavailable Raf inhibitor, with IC₅₀s of 2.1, 4.2, and 2.5 nM for ^V600EΔB-Raf, wt B-Raf, and C-Raf, respectively. ML786 also inhibits Abl-1, DDR2, EPHA2, KDR, and RET (IC₅₀=<0.5, 7.0, 11, 6.2, 0.8 nM). ML786 can be used for the research of cancers.

HY-P991974

Anti-EPHA4 Antibody	Inhibitor
Anti-EPHA4 Antibody is an anti-EPHA4 antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

Name
Email *

	Sorry, but the email address you supplied was invalid.